ArticleESMO open2026

Real-world prognostic assessment of the HERO score in metastatic urothelial carcinoma treated with enfortumab vedotin (ARON-2EV study).

G Roviello et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.